Author(s): Brandão, Ruben ; Marcelino, Rute ; Gonçalves, Fátima ; Diogo, Isabel ; Carvalho, Ana ; Cabanas, Joaquim ; Costa, Inês ; Brogueira, Pedro ; Ventura, Fernando ; Miranda, Ana ; Mansinho, Kamal ; Gomes, Perpétua
Date: 2018
Persistent ID: http://hdl.handle.net/10400.26/30657
Origin: Egas Moniz - Cooperativa de Ensino Superior, CRL
Subject(s): Hepatitis C virus; Direct-acting antivirals; Resistance-associated substitutions; NS5A; NS5B
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This study is focused on the prevalent NS5 coding region resistance-associated substitutions (RASs) in DAA-naive genotype (GT)1 HCV-infected patients and their potential impact on success rates. Plasma RNA from 81 GT1 HCV-infected patients was extracted prior to an in-house nested RT-PCR of the NS5 coding region, which is followed by Sanger population sequencing. NS5A RASs were present in 28.4% (23/81) of all GT1-infected patients with 9.9% (8/81) having the Y93C/H mutation. NS5B RASs showed a prevalence of 14.8% (12/81) and were only detected in GT1b. Overall 38.3% (31/81) of all GT1 HCV-infected patients presented baseline RASs. The obtained data supports the usefulness of resistance testing prior to treatment since a statistically significant association was found between treatment failure and the baseline presence of specific NS5 RASs known as Y93C/H (p = 0.04).
